Synapse - Early Drug Development Service

Results (464)

Comprehensive assessment of RAS/RAF mutation status and identification of alternative targetable driver alterations in RAS/RAF wild type colorectal carcinoma using a hybrid capture-based next-generation sequencing assay

Meeting Abstract

Hechtman, J.; Zehir, A.; Cheng, D.; Shia, J.; Solit, D.; Yaeger, R.; Hyman, D.; Arcila, M.; Berger, M.; Ladanyi, M.; more...
Laboratory Investigation (2015)

Fulltext@MSK | Save

The role of systemic chemotherapy in the management of granulosa cell tumors

Journal Article

Meisel, J. L.; Hyman, D. M.; Jotwani, A.; Zhou, Q.; Abu-Rustum, N. R.; Iasonos, A.; Pike, M. C.; Aghajanian, C.
Gynecologic Oncology (2015)

Fulltext@MSK | Save

Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders

Journal Article

Hyman, D. M.; Diamond, E. L.; Vibat, C. R. T.; Hassaine, L.; Poole, J. C.; Patel, M.; Holley, V. R.; Cabrilo, G.; Lu, T. T.; Arcila, M. E.; more...
Cancer Discovery (2015)

Fulltext@MSK | Save

Early phase I study of the PARP inhibitor veliparib (ART-888) alone or in combination with carboplatia/paclitaxel (CP) in patients with varying degrees of hepatic or renal dysfunction: A study of the NCI-Organ Dysfunction Working Group (ODG)

Meeting Abstract

Tawbi, H. A. H.; Chu, E.; Lin, Y.; Hyman, D. M.; Goel, S.; Rudek, M. A.; Dowlati, A.; LoRusso, P.; Mulkerin, D.; Chew, H. K.; more...
Journal of Clinical Oncology (2014)

Fulltext@MSK | Save

VE-BASKET, a Simon 2-stage adaptive design, phase II, histology-independent study in nonmelanoma solid tumors harboring BRAF V600 mutations (V600m): Activity of vemurafenib (VEM) with or without cetuximab (CTX) in. colorectal cancer (CRC)

Meeting Abstract

Tabernero, J.; Chan, E.; Baselga, J.; Blay, J. Y.; Chau, I.; Hyman, D. M.; Raje, N. S.; Wolf, J.; Sirzén, F.; Veronese, M. L.; more...
Journal of Clinical Oncology (2014)

Fulltext@MSK | Save

A phase 1 study of MEDI3617, a selective angiopoietin-2 inhibitor, alone and in combination with carboplatin/paclitaxel, paclitaxel, or bevacizmab in patients with advanced solid tumors

Meeting Abstract

Hyman, D. M.; Rizvi, N. A.; Natale, R. B.; Armstrong, D. K.; Birrer, M. J.; Recht, L. D.; Dotan, E.; Gribbin, M. J.; McDevitt, J. T.; Tavakkoli, F.; more...
Journal of Clinical Oncology (2014)

Fulltext@MSK | Save

VE-BASKET, a first-in-kind, phase II, histology-independent "basket" study of vemurafenib (VEM) in nonmelanoma solid tumors harboring BRAF V600 mutations (V600m)

Meeting Abstract

Hyman, D. M.; Blay, J. Y.; Chau, I.; Raje, N. S.; Fernandez, M. E. E.; Wolf, J.; Sirzén, F.; Veronese, M. L.; Mitchell, L.; Puzanov, I.; more...
Journal of Clinical Oncology (2014)

Fulltext@MSK | Save

Detection of BRAF mutations in urine and plasma cell-free DNA: Application to the diagnosis and management of histiocytic disorder patients

Meeting Abstract

Abdel-Wahab, O. I.; Diamond, E. L.; Patel, M.; Holley, V. R.; Cabrilo, G.; Rampal, R.; Hassaine, L.; Kosco, K.; Baselga, J.; Kurzrock, R.; more...
Journal of Clinical Oncology (2014)

Fulltext@MSK | Save

Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders

Meeting Abstract

Hyman, D. M.; Diamond, E.; Vibat, C. R.; Hassaine, L.; Poole, J.; Patel, M.; Holley, V.; Cabrilo, G.; Lu, T. T.; Arcila, M.; more...
Blood (2014)

Fulltext@MSK | Save

The efficacy of vemurafenib in Erdheim-Chester disease and Langerhans cell histiocytosis: Preliminary results from VE-basket study

Meeting Abstract

Hyman, D. M.; Diamond, E.; Subbiah, V.; Blay, J. Y.; Lockhart, A. C.; Abdel-Wahab, O.; Sirzén, F.; Veronese, M. L.; Laserre, S. F.; Elez, E.; more...
Blood (2014)

Fulltext@MSK | Save